Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.



George Robinson invests in Oxford spinouts Adaptimmune (ADAP) & Immunocore (IMCR). ADAP listed on Nasdaq in 2015 and IMCR on the same exchange in early 2021.


OIC founded by George Robinson and Ross Hyett.

First exit – Oxitec, purchased by Intrexon Corporation in a $160m cash transaction.


25th OTIF investment in Oxford University spinout OrthoSon, which is revolutionising the treatment of back pain.


£25m raised by OTIF.

First direct co-investment in Diffblue‘s Series A alongside Goldman Sachs.

Christopher Hall joins OIC as Partner, bringing a wealth of legal, corporate finance and early-stage investment experience.


OIC leads Caristo Diagnostics’ £2m Seed round.

James Mallinson joins OIC, bringing a wealth of cross sector Oxford spinout investment experience.

50th OIC investment in Oxford University spinout Oxford Advanced Surfaces, which is transforming how the surface of composite materials are prepared and bonded.


OIC invests in Oxford PV‘s £65m Series D alongside Equinor, Legal & General, Meyer Berger and Xinjiang Goldwind.

OIC moves into Keble College’s H B Allen Centre, the hub of Oxford spinout activity.


OIC recruits world-class Scientific Partners and Commercial Advisory Board.

PhishAR, a company using AI to target phishing attacks, is the 200th spinout from Oxford University.


First investment made in Oxford University spinout SpyBiotech, which is transforming how vaccines to prevent deadly diseases are developed.

OIC makes its fourth investment in ONI‘s $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital, and included Section 32ARTIS VenturesVertical Venture Partners,  Axon Ventures and Oxford Science Enterprises.